-
Oct 2, 2024 | 
jdsupra.com | Helen R. Pfister
This overview is excerpted from Manatt on Health, Manatt’s subscription service that provides in-depth insights and analysis focused on the legal, policy and market developments.
-
Sep 12, 2024 | 
jdsupra.com | Helen R. Pfister
This overview is excerpted from Manatt on Health, Manatt’s subscription service that provides in-depth insights and analysis focused on the legal, policy and market developments.
-
Aug 13, 2024 | 
jdsupra.com | Helen R. Pfister
This overview is excerpted from Manatt on Health, Manatt’s subscription service that provides in-depth insights and analysis focused on the legal, policy and market developments.
-
Jun 25, 2024 | 
mondaq.com | Helen R. Pfister |Julian Polaris
This paper was written in collaboration with Amanda Eiden,
Anthony DiFranzo, Matthew Itzkowitz, and Alexandra Bhatti.
This is an excerpt from a recently published study in AJMP
Focus, "State Medicaid Coverage and Reimbursement of Adult
Vaccines Administered by Physicians and Pharmacists as of
2022", which was supported by Merck. Click here to read the full article.
-
Jun 24, 2024 | 
mondaq.com | Helen R. Pfister |Julian Polaris
This is an excerpt from a recently published study in AJMP
Focus, "State Medicaid Coverage and Reimbursement of Adult
Vaccines Administered by Physicians and Pharmacists as of
2022", which was supported by Merck. Click here to read the full
article.
Effective October 2023, federal law requires Medicaid programs
to cover all recommended adult vaccines administered by physicians
with no cost sharing for all eligibility groups. However, uniform
coverage does not always translate to optimal uptake.
-
Jun 3, 2024 | 
mondaq.com | Helen R. Pfister
This overview is excerpted from Manatt on Health,
Manatt's subscription service that provides in-depth insights
and analysis focused on the legal, policy and market
developments.
On May 21, the U.S. Court of Appeals for the District of
Columbia Circuit upheld the right of pharmaceutical manufacturers
to place at least some restrictions on the shipment of 340B drugs
to contract pharmacies of 340B covered entities. The decision, in
Novartis Pharmaceuticals Corporation v.
-
May 30, 2024 | 
jdsupra.com | Helen R. Pfister
This overview is excerpted from Manatt on Health, Manatt’s subscription service that provides in-depth insights and analysis focused on the legal, policy and market developments. On May 21, the U.S. Court of Appeals for the District of Columbia Circuit upheld the right of pharmaceutical manufacturers to place at least some restrictions on the shipment of 340B drugs to contract pharmacies of 340B covered entities. The decision, in Novartis Pharmaceuticals Corporation v.
-
Jun 7, 2023 | 
mondaq.com | Helen R. Pfister |Julian Polaris |Matthew Itzkowitz
Editor's Note: In a new white paper funded by Pfizer, Inc.,
Manatt Health discusses the current landscape of Medicaid and
Children's Health Insurance Program (CHIP) coverage and
reimbursement for prenatal vaccines, informed by a recent
assessment of relevant policies in all 50 states, plus Washington,
D.C., and Puerto Rico.
-
Jun 6, 2023 | 
jdsupra.com | Matthew Itzkowitz |Helen R. Pfister |Julian Polaris
Editor’s Note: In a new white paper funded by Pfizer, Inc., Manatt Health discusses the current landscape of Medicaid and Children’s Health Insurance Program (CHIP) coverage and reimbursement for prenatal vaccines, informed by a recent assessment of relevant policies in all 50 states, plus Washington, D.C., and Puerto Rico.
-
May 26, 2023 | 
mondaq.com | Helen R. Pfister |Julian Polaris |Matthew Itzkowitz
Prenatal vaccines—those administered during a
pregnancy—provide crucial protections to pregnant women
and/or newborns against communicable diseases such as whooping
cough and influenza. Additional prenatal vaccines are in the
pipeline, including a vaccine against infant respiratory syncytial
virus (RSV).
Despite the demonstrated effectiveness of prenatal vaccines,
fewer than one out of four pregnant women receives all federally
recommended vaccines.
